These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Meyskens FL; Gerner EW Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725 [TBL] [Abstract][Full Text] [Related]
3. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary. Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372 [TBL] [Abstract][Full Text] [Related]
4. Use of in vitro assays to predict the efficacy of chemopreventive agents in whole animals. Steele VE; Sharma S; Mehta R; Elmore E; Redpath L; Rudd C; Bagheri D; Sigman CC; Kelloff GJ J Cell Biochem Suppl; 1996; 26():29-53. PubMed ID: 9154167 [TBL] [Abstract][Full Text] [Related]
6. Cancer prevention research: back to the future. Lippman SM Cancer Prev Res (Phila); 2009 Jun; 2(6):503-13. PubMed ID: 19491288 [No Abstract] [Full Text] [Related]
7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials. Greenwald P J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595 [TBL] [Abstract][Full Text] [Related]
8. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594 [TBL] [Abstract][Full Text] [Related]
9. Cancer chemoprevention drug targets. Krishnan K; Campbell S; Abdel-Rahman F; Whaley S; Stone WL Curr Drug Targets; 2003 Jan; 4(1):45-54. PubMed ID: 12528989 [TBL] [Abstract][Full Text] [Related]
11. The chemopreventive agent development research program in the Division of Cancer Prevention of the US National Cancer Institute: an overview. Crowell JA Eur J Cancer; 2005 Sep; 41(13):1889-910. PubMed ID: 16005206 [TBL] [Abstract][Full Text] [Related]
12. Mechanistic considerations in the evaluation of chemopreventive data. Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet RA; Greenwald P; Hawk ET; Fay JR; Sigman CC IARC Sci Publ; 1996; (139):203-19. PubMed ID: 8923032 [TBL] [Abstract][Full Text] [Related]
16. Strategy and planning for chemopreventive drug development: clinical development plans II. Kelloff GJ; Crowell JA; Hawk ET; Steele VE; Lubet RA; Boone CW; Covey JM; Doody LA; Omenn GS; Greenwald P; Hong WK; Parkinson DR; Bagheri D; Baxter GT; Blunden M; Doeltz MK; Eisenhauer KM; Johnson K; Knapp GG; Longfellow DG; Malone WF; Nayfield SG; Seifried HE; Swall LM; Sigman CC J Cell Biochem Suppl; 1996; 26():54-71. PubMed ID: 9154168 [TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of cancer. Tsao AS; Kim ES; Hong WK CA Cancer J Clin; 2004; 54(3):150-80. PubMed ID: 15195789 [TBL] [Abstract][Full Text] [Related]
18. The role of chemoprevention in cancer control. Greenwald P; Kelloff GJ IARC Sci Publ; 1996; (139):13-22. PubMed ID: 8923016 [TBL] [Abstract][Full Text] [Related]
19. Cancer prevention by protease inhibitors. Kennedy AR Prev Med; 1993 Sep; 22(5):796-811. PubMed ID: 8234219 [TBL] [Abstract][Full Text] [Related]
20. Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression. Lubet RA; Steele VE; Shoemaker RH; Grubbs CJ Cancer Prev Res (Phila); 2018 Oct; 11(10):595-606. PubMed ID: 30045934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]